Peptide blend
BPC-157 + TB-500
A pre-mixed vial of BPC-157 and TB-500. In a 2026 rat tendon study of both peptides, the authors report no additional benefit over either alone.1
BPC-157 + TB-500 after one dose: 50% at ~1.25 h, 25% at 2.5 h, 12.5% at 3.75 h.
Drawn from the half-life in the app's model, ~1.25 h. The model's figures
- Compound
- BPC-157 + TB-500
- Symbol
- B+T
- Family
- Healing peptides
- Parts
- 14
- References
- 15
- Checked
- Last reviewed . Sources are listed below.
How Milligram users log it

7%The 8th most tracked compound in Milligram: of people who track compounds in Milligram logged BPC-157 + TB-500 in the last 90 days.
Schedule
Logged doses
Half of people logged between 1 and 3.75 mg per dose; the median was 1 mg.
Tracked alongside
The share of people logging BPC-157 + TB-500 who also logged each.
From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.
Overview
The app lists BPC-157 + TB-500 as a pre-mixed blend of 10 mg BPC-157 and 10 mg TB-500, 20 mg in total per vial, also known as BPC+TB and as the "wolverine" blend.
BPC-157 is described by Poolton and colleagues (Acta Orthopaedica Belgica, 2026) as a synthetic pentadecapeptide that lacks regulatory approval for human use, with evidence "largely limited to animal models".2 FDA's briefing document on TB-500 says it "is understood today to be a seven amino acid synthetic fragment of thymosin beta-4" covering amino acids 17 to 23, with an acetyl group at the N-terminal leucine.3
Sources describe TB-500 differently: the 2026 rat study below calls it "synthetic thymosin beta-4 (TB-500)", while Tham and colleagues (Journal of the American Academy of Orthopaedic Surgeons, 2026) call it "a distinct seven amino-acid fragment of TB-4 that is frequently conflated with full-length TB-4 despite the absence of validated biologic or clinical equivalence".1,4
The figures at the top and the Moderate Evidence badge are the app's own, not measurements of the blend. The app grades the evidence for the blend as moderate; Poolton and colleagues rated the overall certainty of evidence for BPC-157 in people as very low, after a systematic review that included three studies with 30 people in total.2
A search of PubMed on 16 November 2026 for BPC-157 together with TB-500 or thymosin in the title or summary text returned 15 records; 12 are review articles and 3 report animals or people given BPC-157 with TB-500 or thymosin beta-4: the 2026 rat study, a 2021 knee chart review and a 2026 case report. It may miss records that write BPC157 or TB500.
A ClinicalTrials.gov search on the same date for BPC-157 and TB-500 together returned no registered study.
How it works
BPC-157
FDA's briefing document on BPC-157 states that "the molecular targets for BPC-157 have not been identified and its mechanisms of action remain poorly understood".5 McGuire and colleagues (University of Utah, Current Reviews in Musculoskeletal Medicine, 2025) write that BPC-157 "activates several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis", and that it "demonstrates robust regenerative and cytoprotective effects in preclinical studies".6
TB-500
FDA's briefing document states that the segment LKKTET of the TB-500 sequence is known as the actin-binding region of thymosin beta-4, and that it has been hypothesised that LKKTETQ may share thymosin beta-4's G-actin buffering capacity.3 It also describes an 8-hour cell-culture study in which TB-500 at 50 µg/mL was not significantly different from vehicle for wound closure in scratched fibroblast cultures, while its metabolite N-acetylated LKKTE caused a small but significant wound closure.3 FDA notes that the study lacks a concentration-response relationship analysis.3 FDA states that "It remains unknown whether TB-500 (free base) and TB-500 acetate could have" wound-healing properties in vivo.3
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~1.25 h
- Bioavailability
- 95%
- Typical dose
- 1–4 mg/day
- Route
- SubQ
- Time to peak
- ~0.5 h
The sources cited here contain no pharmacokinetic measurement of the blend; the table sets the app's figures beside what the sources report for each peptide alone.
| Figure | The app's figure | What the sources report |
|---|---|---|
| Half-life | ~1.25 hours | BPC-157 alone: an elimination half-life of less than 30 minutes after intravenous and intramuscular doses in rats and beagle dogs,7 and 5.3 minutes in dogs to 15.2 minutes in rats after one intravenous dose in FDA's account of the same study.5 TB-500 alone: no half-life reported in the sources cited. |
| Bioavailability (SubQ) | 95% | BPC-157 alone, intramuscular: a mean absolute bioavailability of about 14% to 19% in rats and 45% to 51% in beagle dogs.7 TB-500 alone: no absolute bioavailability, because the horse study gave no intravenous dose.3 |
| Time to peak | ~0.5 hours | TB-500 alone, 10 mg subcutaneously in horses: plasma concentrations peaked at 0.05 and 0.08 ng/mL between 60 and 120 minutes and were unquantifiable between 6 and 10 hours after the dose.3,8 No time to peak for BPC-157 in the sources cited. |
| Route | SubQ | Rat study: intraperitoneal. Knee chart review: intra-articular. Nerve-injury cases: submucosal injection. FDA adverse event report of a BPC-157 and TB-500 product: subcutaneous, twice daily.5 FDA's TB-500 briefing: proposed for the intramuscular and subcutaneous routes.3 |
FDA found no human pharmacokinetic data for BPC-157 after oral, subcutaneous, nasal or transdermal doses, and did not identify clinical studies in humans assessing the pharmacokinetics of TB-500 by any route.5,3 In two rectal-enema studies of BPC-157, FDA reports that the authors did not detect it in plasma samples, and in one meeting report (Veljaca and colleagues, 2003) the authors state that "most" plasma concentrations were below the lower limit of quantification.5 He and colleagues (Air Force Medical University, Xi'an, Frontiers in Pharmacology, 2022) report that BPC-157 showed linear pharmacokinetics at all doses in rats and beagle dogs, with urine and bile as the main excretory pathways, and the authors declare no commercial or financial relationships that could be a conflict of interest.7 The authors state that they had "previously established a solid-phase synthesis process for BPC157" and that the study "will be helpful for its translation in the clinic".7
Human studies
Two published reports describe people who received BPC-157 together with TB-500 or thymosin beta-4, and neither has a control group. The one controlled study found of both peptides together was in rats and is described below the table.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Lee and Padgett, Alternative Therapies in Health and Medicine, 20219 | Retrospective chart review at the Institute for Hormonal Balance, Orlando, Florida, with a phone survey; BPC 157 alone or with thymosin-beta-4 (TB4), which the record does not state to be TB-500 | 17 patients in the review; 16 reached by phone: 12 given BPC 157 alone, 4 given BPC 157 with TB4 | Intra-articular knee injection; BPC-157 2 to 4 mg in 1 to 2 doses according to FDA's table, TB4 dose not stated; most injections 6 months to 1 year before the survey | BPC 157 alone: 11 of 12 (91.6%) reported significant improvement in knee pain and 1 of 12 reported no improvement. With TB4 (4 patients): 75% significant improvement and 25% no relief. No specific tools measured function, quality of life, stiffness or activities of daily living.9 |
| Froum and colleagues, Frontiers in Oral Health, 202610 | Case report of inferior alveolar nerve injury after dental surgery, treated with a multi-agent protocol; no control group | 3 patients, aged 38, 85 and 48 years | Weekly submucosal injections for 4 weeks of ARA-290 4 mg, TB-500 10 mg, BPC-157 1 mg, dexamethasone 8 mg and bupivacaine 0.5% with epinephrine | Near-complete resolution in cases 1 and 2, and a nearly 95% reduction in subjective numbness in case 3; adverse events none reported. The authors state the uncontrolled observation does not establish a causal association. |
Deeper analysis: the 2026 rat study of BPC-157 and TB-500 together
Biçer and colleagues (Bağcılar Training and Research Hospital, Istanbul; Joint Diseases and Related Surgery, 2026) randomised 32 male Sprague-Dawley rats into four groups of 8 after a full transverse Achilles tendon cut and repair: control, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, and both, each given intraperitoneally every day for 30 postoperative days.1 Four tendons per group went to mechanical testing and four to microscopy, so "the effective sample size for all nonbiomechanical analyses reported in this manuscript was n = 4 per group".1
Median maximum load to failure was 26.91 N in controls, 37.16 N with BPC-157, 37.41 N with TB-500 and 34.54 N with both.1 The only significant pairwise difference was TB-500 against controls (adjusted p = 0.0406); BPC-157 did not differ from controls (adjusted p = 0.389) and the combined group did not differ from any group.1 The total Movin score was lower than in controls with TB-500 (p = 0.017) and with the combination (p = 0.040) but not with BPC-157 (p = 0.601), and the total Bonar score was lower only with TB-500 (p = 0.016).1 Type I collagen intensity on Sirius red was higher than in controls with BPC-157 (p = 0.009) and TB-500 (p = 0.041), and immunohistochemistry showed no significant difference in collagen type I expression (p = 0.242).1 Collagen type III expression differed significantly among groups on immunohistochemistry, type III intensity on Sirius red differed between the BPC-157 and TB-500 groups (p = 0.028), and the authors write that the significantly elevated collagen type III score in the TB-500 group "warrants careful interpretation".1 Collagen alignment differed significantly only between controls and TB-500 (p = 0.049), and vascularity did not differ (p = 0.108).1 No statistically significant differences were observed among the treatment groups on the Movin score, and the authors report that "Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone".1
The authors list as limitations a single time point four weeks after repair, healthy young male rats, no functional assessment, no molecular analyses, a TB-500 dose chosen from the broader thymosin beta-4 literature, histology on 4 animals per group with "a prospective a priori power calculation" not performed, no assessment of interobserver reliability, no measurement of tendon cross-sectional area, biomechanical testing limited to maximum load to failure, and no blinding during surgery or daily treatment.1 A pathologist blinded to group allocation scored the histology, and biomechanical testing used coded specimens to ensure assessor blinding.1 The study reports no animal deaths or postoperative infections, the authors declared no conflicts of interest and received no financial support, and both peptides came from Peptide Sciences (Boca Raton, Florida).1
Deeper analysis: the 2021 knee chart review
Lee and Padgett reviewed charts from 2019 to 2020 at the Institute for Hormonal Balance in Orlando, Florida, and phoned 16 of 17 patients who had received knee injections of BPC 157 alone (12 patients) or with thymosin-beta-4 (4 patients).9 Follow-up varied because the study was retrospective, and patients rated their own pain by phone.9 Tham and colleagues call the human musculoskeletal evidence for BPC-157 "one small retrospective uncontrolled case series without validated outcome measures".4 The PubMed record carries no funding or conflict-of-interest statement for the review.9
Deeper analysis: the 2026 nerve-injury case report
Froum and colleagues (Stony Brook University School of Dental Medicine, Lake Erie College of Osteopathic Medicine and a private practice) describe three patients with inferior alveolar nerve injury after implant placement, implant removal or extraction who received weekly submucosal injections for 4 weeks of ARA-290, TB-500, BPC-157, dexamethasone and bupivacaine, so TB-500 and BPC-157 were among several agents given together.10 They list "Limited sample size, absence of a control group, and treatment allocation were not randomized" among the limitations, and state that no validated outcome measures or quantitative sensory testing were obtained prospectively.10 They also write that "it is impossible to determine whether the observed clinical course resulted from one agent, a combination of agents, associations among interventions, or the expected natural history of recovery".10 The authors declared no commercial or financial relationships and no financial support.10
The components in people, one at a time
The three BPC-157 studies in Poolton and colleagues' systematic review were a retrospective knee pain study (n=16), a retrospective pilot study of intravesical injections for interstitial cystitis (n=12) and a prospective pilot of intravenous safety (n=2); all reported symptom improvement in most participants without treatment-related adverse events, and were judged to be of poor quality.2 FDA's BPC-157 briefing counts five clinical studies of BPC-157, among them a randomised, double-blind, placebo-controlled enema study in ulcerative colitis (80 mg daily for 2 weeks, 53 people randomised) and an enema study in 24 healthy people.5 For TB-500, FDA's briefing document, dated 15 May 2026, states that it "has not identified, any clinical studies or human exposure data using TB-500 via any ROA", where ROA is route of administration.3
Doses reported in studies
The app lists a typical dose of 1–4 mg/day for the blend. None of the studies below reports a daily dose in mg for both peptides together. No approved label exists for either peptide, so there is no label dose.5,3
| Source | Substance and route | Dose | Frequency and length |
|---|---|---|---|
| Rat Achilles tendon study, 20261 | BPC-157 and TB-500, intraperitoneal, rats | BPC-157 10 µg/kg/day; TB-500 60 µg/kg/day; both in the combined group | Once daily for 30 postoperative days |
| Knee chart review, 20219,5 | BPC 157 alone or with thymosin-beta-4, intra-articular, knee | BPC-157 2 to 4 mg; TB4 dose not stated | 1 to 2 doses |
| Nerve-injury case report, 202610 | ARA-290, TB-500, BPC-157, dexamethasone and bupivacaine, submucosal injection | ARA-290 4 mg; TB-500 10 mg; BPC-157 1 mg; dexamethasone 8 mg | Weekly for 4 weeks |
| BPC-157 alone: interstitial cystitis, 202411 | BPC-157 alone, injected around the inflamed area of the bladder during cystoscopy | 10 mg in total | Single procedure; 12 women |
Side effects reported
Reports that involve both peptides
FDA's BPC-157 briefing summarises a report to its adverse event database of a 40-year-old woman who used a subcutaneous product containing BPC-157 and TB500 twice daily, labeled for "research purposes only", and who developed "diffuse hyperpigmentation and gingival darkening following initial use of the product containing BPC-157 and TB500 for one week".5 The same reactions reproduced on rechallenge, the patient stopped all peptides and had no further reactions, and FDA writes that "The AEs were likely due to the drug product considering that the AEs occurred upon rechallenge; however, because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported AEs".5 FDA's TB-500 briefing adds that a search of its human foods complaint system for 1/1/2004 to 3/10/2025 retrieved two cases about "blended TB-500 and BPC-157", and that the reports did not include safety assessments.3
Reports on each peptide and in the studies
FDA's adverse event database returned no reports for TB-500 through 26 March 2025, and three reports for BPC-157 through 4 December 2025: the blend report above, 9 days of redness and swelling around the injection site in a woman who also used injectable compounded thymosin, and shortness of breath leading to an emergency room visit in a man, with no further information.3,5 FDA states it "cannot make definitive conclusions regarding the safety of BPC-157 based on FAERS data alone".5 In FDA's table for the knee chart review the safety finding is quoted as "This peptide was well tolerated with no adverse events noted", the nerve-injury report lists no adverse events, and the rat study reports no animal deaths or postoperative infections.5,10,1 None of these is a controlled safety study; Poolton and colleagues found no treatment-related adverse events in the three BPC-157 human studies but rated them poor in quality.2 FDA says no serious adverse events appear to have been reported in its five BPC-157 clinical studies, which were short, small and gave limited safety data, and quotes the healthy-volunteer enema study as reporting headache and flatulence that "occurred with no obvious difference in frequency or severity" between study product and placebo dosing.5
Product quality and immunogenicity
Tham and colleagues write that commercial products marketed as these peptides "raise concerns regarding identity, purity, concentration, sterility, and manufacturing consistency".4 FDA's TB-500 briefing says that peptides given by injection "may pose a significant risk for immunogenicity, potentially amplified by aggregation as well as potential peptide-related impurities", and that the potential safety risks in humans are unknown.3 A chemistry study of Esposito and colleagues (Ghent University, Drug Testing and Analysis, 2012) identified the N-terminal acetylated 17-23 fragment of thymosin beta-4 in a TB-500 product.13
Bloodwork and markers
Sources in this part
The app lists no markers to monitor for this blend. In the intravenous pilot of BPC-157 alone, 2 adults, each of whom had received intravenous BPC-157 before the trial, had blood work and vital signs before and after infusions of 10 mg and 20 mg, and the infusions "resulted in no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels".12
Regulatory and anti-doping status
FDA published separate briefing documents on BPC-157 and on TB-500 for the Pharmacy Compounding Advisory Committee meeting of July 23 to 24, 2026; each states, as of the briefing document, that the substance is not a component of an FDA-approved drug and proposes not adding it to the 503A Bulks List.5,3 FDA states that it "will not issue a final determination" on the issues until input from the advisory committee process has been considered, and the sources cited here do not report the committee's vote or a final determination.5
FDA's BPC-157 briefing also mentions one adverse event report on a BPC-157 and TB-500 (5mg/5mg) injection product, where the app lists 10 mg of each peptide.5
Tham and colleagues write that none of BPC-157, thymosin beta-4 or TB-500 has "an FDA-approved musculoskeletal indication, validated orthopaedic treatment protocol, or controlled human orthopaedic efficacy evidence".4
| Peptide | FDA, July 2026 briefing documents | WADA 2026 Prohibited List |
|---|---|---|
| BPC-1575,14 | Proposal not to add BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List | Named in S0 non-approved substances, prohibited at all times, in and out of competition; S0 substances are Specified Substances |
| TB-5003,14 | Proposal not to add TB-500 (free base) or TB-500 acetate to the 503A Bulks List | Named in S2.3 growth factors and growth factor modulators as "Thymosin-ß4 and its derivatives e.g. TB-500"; S2 is prohibited at all times, in and out of competition, and non-Specified |
The WADA 2026 list came into effect on 1 January 2026.14
What is not known
It is not known whether the two peptides add to each other in people. The rat study analysed 4 tendons per group in each analysis and reported no additional benefit from the combination over either agent alone; the combined group differed from controls on the total Movin score (p = 0.040) and BPC-157 alone did not (p = 0.601).1
Tham and colleagues state that "Validated dosing, pharmacokinetic, and long-term safety data are lacking" for BPC-157.4
What TB-500 is differs between sources, and FDA writes that "TB-500 is a common name and not a United States Adopted Name" and that it "has encountered multiple salts, and derivatives, including different active moieties, sold commercially under the same common name".3
ClinicalTrials.gov lists a Phase 1/2 trial of TB-500 alone against placebo in adults with stable atherosclerotic cardiovascular disease (NCT07487363, sponsor Hudson Biotech, started 5 February 2026, an estimated 80 participants), shown as recruiting on 16 November 2026.15
Frequently asked questions
What is in a BPC-157 + TB-500 vial?
The app lists 10 mg of BPC-157 and 10 mg of TB-500 in one pre-mixed vial, 20 mg in total. FDA's BPC-157 briefing describes one adverse event report on a BPC-157 and TB-500 (5mg/5mg) injection product, a different strength from the app's.5
What is the half-life of BPC-157 + TB-500?
The app lists a half-life of about 1.25 hours for the blend, and the sources cited contain no measurement of the blend's half-life. For BPC-157 alone, FDA reports 5.3 minutes in dogs to 15.2 minutes in rats after one intravenous dose.5 No half-life is reported for TB-500 in the sources cited.
Has BPC-157 been studied together with TB-500?
A search of PubMed on 16 November 2026 found one rat study of BPC-157 and TB-500 together.1 Two small human reports, neither with a control group, involved BPC-157 with a thymosin beta-4 product (4 knee patients) or with TB-500 among several agents (3 nerve-injury patients).9,10 A ClinicalTrials.gov search on 16 November 2026 for the two together returned no registered study.
Do BPC-157 and TB-500 work better together?
Is BPC-157 + TB-500 banned by WADA?
Both peptides are named on the WADA 2026 Prohibited List: BPC-157 in section S0 and TB-500 in section S2.3, each prohibited at all times, in and out of competition.14
Is BPC-157 + TB-500 approved by the FDA?
What side effects have been reported for BPC-157 + TB-500?
FDA's BPC-157 briefing describes one adverse event report on a product with both peptides: diffuse hyperpigmentation and gingival darkening in a 40-year-old woman, reproduced on rechallenge.5 FDA says that, because the product contained two peptides, it is not possible to assess a potential relationship between BPC-157 and those events.5 FDA's TB-500 briefing adds two reports about "blended TB-500 and BPC-157" in its human foods complaint system, without safety assessments.3
What is TB-500?
FDA's briefing document describes TB-500 as a seven amino acid synthetic fragment of thymosin beta-4, amino acids 17 to 23, with an acetyl group at the N-terminal leucine.3
What dose of BPC-157 and TB-500 was used in studies?
The 2026 rat study gave BPC-157 at 10 µg/kg/day and TB-500 at 60 µg/kg/day intraperitoneally, daily for 30 days.1 The app lists 1–4 mg/day, and no study cited reports that daily dose for the blend.
Guides, tools and comparisons
References
- Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg 2026. Joint Dis Relat Surg, full text
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg 2026. PMID 42885452
- US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23 - 24, 2026: TB-500-Related Bulk Drug Substances (TB-500 (Free Base) and TB-500 acetate). 2026. FDA briefing document
- Tham A, Hodgkins CW, Kennedy JG. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. J Am Acad Orthop Surg 2026. PMID 42937313
- US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23 - 24, 2026: BPC-157 – Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate). 2026. FDA briefing document
- McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med 2025. PMID 40789979
- He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol 2022. PMID 36588717
- Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta-4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A 2012. PMID 23084823
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med 2021. PMID 34324435
- Froum S, Estrin N, Pico G, et al. Case Report: Regenerative peptides for inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health 2026. PMC13661421
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med 2024. PMID 39325560
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med 2025. PMID 40131143
- Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal 2012. PMID 22962027
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. 2026. WADA 2026 list
- Hudson Biotech. A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study of TB-500 (Thymosin Beta 4 17-23 Fragment) in Adults With Stable Atherosclerotic Cardiovascular Disease. ClinicalTrials.gov NCT07487363, 2026. NCT07487363